<DOC>
	<DOC>NCT00558285</DOC>
	<brief_summary>An investigational inhalation product (QVA149) for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) is being developed. This 14 day study will investigate the effect on heart rate and cardiovascular effects to ensure the product is safe.</brief_summary>
	<brief_title>Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Consented male or female adults aged ≥40 years Moderate to severe stable Chronic Obstructive Pulmonary Disease (COPD) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines (2006) Patients who have smoking history of at least 10 pack years Patients with a postbronchodilator Forced Expiratory Volume in one second (FEV1) ≥30% and &lt;80% of the predicted normal and postbronchodilator FEV1/Forced vital capacity (FVC) &lt;0.70 at Visit 1 and Visit 3 Pregnant or nursing (lactating) women Patients requiring long term oxygen therapy (&gt; 15 hours a day) on a daily basis for chronic hypoxemia, or who have been hospitalized or visited an emergency room for a COPD exacerbation in the 6 weeks prior to screening (Visit 1) or during the screening period Patients who had a respiratory tract infection within 6 weeks of Visit 1 or at screening Concomitant pulmonary disease, pulmonary tuberculosis (TB) (unless chest xray confirms no longer active) or clinically significant bronchiectasis Any history of asthma Patients who have clinically relevant lab abnormalities / conditions such as (but not limited to) long term prednisone therapy, unstable ischemic heart disease, left ventricular failure, history of myocardial infarction, arrhythmia (excluding stable atrial fibrillation [AF]), uncontrolled hypertension, narrowangle glaucoma, symptomatic prostatic hyperplasia or bladderneck obstruction or moderate to severe renal impairment, uncontrolled hypo and hyperthyroidism, hypokalemia, hyperadrenergic state or any condition which might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study Patients with a history of cardiac failure, life threatening arrhythmias (screening Holter) and acute ischemic changes (screening ECG) Patients with a history of long QT syndrome or whose QTc (Fridericia method) interval measured at screening (Visit 1) is prolonged (&gt;450 ms for males or &gt;470 for females) History of malignancy of any organ system, treated or untreated within the past 5 years Uncontrolled Type I / Type II Diabetes or blood glucose outside the normal range or Hemoglobin A1C (HbA1c) &gt;8.0% of total hemoglobin measured at Visit 1 Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Indacaterol</keyword>
	<keyword>QVA149</keyword>
</DOC>